The INCATE Selection Committee selected the new 4 ventures for Stage I support. Meet the new additions to the INCATE family: Arvalus Therapeutics - Arvalus is pioneering a next-generation live biotherapeutic product (LBP) engineered to [...]
More news
Puray, together with Munich University of Applied Sciences, has been awarded a prestigious €300k grant [...]
Photo credits: Phiogen PHIOGEN, a Texas-based venture developing off-the-shelf live biotherapeutic products, is excited [...]
Photo credits: INCATE Cavenagh Health exists to foster innovation and support the creation of new [...]
Antimicrobial resistance (AMR) is a global growing threat. Only through closer collaboration across all [...]
September 19th, 2024 – INCATE, the INCubator for Antibacterial Therapies in Europe, is glad to [...]
September 10th, 2024 – INCATE, the INCubator for Antibacterial Therapies in Europe, is pleased [...]
September 2nd, 2024 - INCATE (the INCubator for Antibacterial Therapies in Europe) is celebrating its [...]
The INCATE Selection Committee selected the new 6 ventures for Stage I support. Meet [...]
